• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Quantum Biopharma Ltd.

    6/2/26 11:50:53 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QNTM alert in real time by email
    6-K 1 qntm6k060226.htm FORM 6-K

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    Form 6-K

     

     

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of June 2026

     

    Commission File Number: 001-39152

     

     

     

    Quantum Biopharma Ltd.
    (Registrant)

     

     

     

    1 Adelaide Street East, Suite 801

    Toronto, Ontario M5C 2V9

    (Address of principal executive office)

     

     

     

    Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒     Form 40-F ☐

     

     

     

     

     

     

    DOCUMENTS INCORPORATED BY REFERENCE

     

    Exhibit 99.1 of this Form 6-K is hereby incorporated by reference into the Registrant’s Registration Statement on Form F-3 (File No. 333-276264) and shall be deemed to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      

     

    Quantum Biopharma Ltd.

    (Registrant)

         
    Date: June 2, 2026

    By: /s/ Donal Carroll
        Donal Carroll
    Chief Financial Officer

     

    2

     

     

    EXHIBIT INDEX

     

    Exhibit   Description of Exhibit
       
    99.1   Press Release dated June 1, 2026 – Quantum BioPharma Provides Corporate Update

     

    3

     

     

    Get the next $QNTM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QNTM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $QNTM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.

    Disseminated on behalf of Quantum BioPharma, may include paid advertisements. AUSTIN, Texas, June 02, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Anthony Durkacz, Co-Founder and Executive Co-Chair of Quantum BioPharma Ltd. (NASDAQ:Q

    6/2/26 8:00:00 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns

    TORONTO, June 02, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum" or the "Company"), a biopharmaceutical company focused on advancing innovative therapies and technologies, is pleased to announce that it has entered into an investor relations and consulting services agreement with Stocks.news through IR Agency LLC (the "Agency") beginning on June 8, 2026. Pursuant to the agreement, the Agency has agreed to communicate information about the Company, but not limited to, creating company profiles and media distribution to the financial community, building a digital community with respect to the Company, marketing of news distribution and also l

    6/2/26 7:40:00 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum BioPharma Provides Corporate Update

    THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, June 01, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum" or the "Company"), a biopharmaceutical company focused on advancing innovative therapies and technologies, today provided an update regarding its Investigational New Drug application for Lucid-21-302 (Lucid-MS), the Company's drug candidate for the treatment of multiple sclerosis (MS). On May 28, 2026, the Company received correspondence from the U.S. Food and Drug Administration ("FDA") indicating that th

    6/1/26 7:30:00 PM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QNTM
    SEC Filings

    View All

    SEC Form 6-K filed by Quantum Biopharma Ltd.

    6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

    6/2/26 11:50:53 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Quantum Biopharma Ltd.

    6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

    6/2/26 7:40:04 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Quantum Biopharma Ltd.

    6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

    5/18/26 6:00:09 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QNTM
    Leadership Updates

    Live Leadership Updates

    View All

    Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026

    TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum" or the "Company"), has reported its financial and operational results for the first quarter of 2026, ended March 31, 2026. First Quarter 2026 Financial Results As of March 31, 2026, the Company's combined cash and cash equivalents, and digital assets, totaled US$9.8 million, more than doubled from US$4.1 million as of December 31, 2025. Management confirms that current liquidity is sufficient to fund planned operations to approximately July 2027. As of the date of this press release, the fair market value of the Company's cryptocurrency portfolio is US$6.5 million, further st

    5/7/26 7:00:00 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant

    TORONTO, April 22, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that Unbuzzd Wellness Inc. (formerly, Celly Nutrition Corp.) (the "Company"), the company behind unbuzzd™, the scientifically-proven beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms, is pleased to announce the appointment of Mr. Richard Buzbuzian as Chief Executive Officer. This marks a pivotal milestone in the Company's commercialization strategy. With the functional beverage market projected to reac

    4/22/26 9:16:08 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis

    TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced the appointment of Dr. Salvatore Napoli, MD, as Principal Investigator for its planned Phase 2 clinical trial evaluating Lucid-21-302 (Lucid-MS), an investigational therapy being developed to target demyelination in Multiple Sclerosis (MS). Dr. Salvatore Napoli, is an internationally recognized neurologist and key opinion leader in MS, with over 20 years of clinical and research experience. He is President and Medical Director

    3/26/26 8:00:00 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QNTM
    Financials

    Live finance-specific insights

    View All

    Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend

    TORONTO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces the expiration at 5pm EST of 53,147 warrants (originally 3,454,543 warrants issued pre-reverse stock split (65 to 1)). All warrants were issued to hedge funds and investment funds as part of a previous financing completed on October 20, 2020. This represen

    10/20/25 8:30:00 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case

    TORONTO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announced today that its Board of Directors has established October 27, 2025 as the record date for the distribution of contingent value rights ("CVRs") to holders of its Class B Subordinate Voting Shares on a one-for-one basis, advancing the Company's previously disclosed plan in the Company's press release dated June 13, 2025, to deliver a litigation-linked CVR to shareholders of record as of the record date. Each CVR will entitle the holder

    10/3/25 7:00:00 AM ET
    $QNTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quantum BioPharma Makes Strategic Investment in GameStop Corp.

    TORONTO, July 22, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to innovative therapies for neurodegenerative disorders, today announced the purchase of 2,000 shares of GameStop Corp. (NYSE:GME) to hold on the Company's balance sheet as a strategic investment. This move aligns with Quantum BioPharma's ongoing commitment to combating market corruption and enhancing shareholder value through prudent financial strategies and advocacy against manipulative trading practices. The Company has been at the forefront of fighting market corruption, as evidenced by

    7/22/25 7:00:00 AM ET
    $GME
    $QNTM
    Electronics Distribution
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care